All AbMole products are for research use only, cannot be used for human consumption.
CI-994 (N-acetyldinaline) is a novel oral agent which inhibits HDAC1, with a wide spectrum of antitumor activity in preclinical models, in vitro and in vivo. CI-994 inhibits growth of LNCaP cell with IC50 of 7.4 μM. CI-994 inhibits growth of rat leukemia BCLO cells with IC50 of 2.5 μM. The effect of CI-994, as demonstrated by recovery experiments, was cytostatic and seemed to be superimposable in both cell lines. Cytofluorimetric analysis to assess cell cycle perturbation and apoptosis was performed after 24 h of treatment, indicating a cell block with concomitant increase at G0/G1 phase, a reduction at S phase level at 20, 40, 80, and 160 microM, and apoptosis at the higher concentration (160 microM). CI-994 is currently in a phase III clinical trial in patients with lung cancer.
University of Otago. 2019.
Transcriptional effects of mood stabiliser drugs in a serotonergic cell line
CI-994 purchased from AbMole
 |
Source | AIDS Res Hum Retroviruses (2016). Figure 3. CI-994 |
| Method | Immunoblots | |
| Cell Lines | CD4+ T cells | |
| Concentrations | 0.57 μM | |
| Incubation Time | 24 h | |
| Results | Both vorinostat and panobinostat, but not tacedinaline, increased CDK9 T-loop phosphorylation in CCL19-treated cells compared to control cells. Vorinostat and panobinostat, but not tacedinaline, also increased histone H3 acetylation in CCl19-treated cells. |
| Molecular Weight | 269.3 |
| Formula | C15H15N3O2 |
| CAS Number | 112522-64-2 |
| Solubility (25°C) | DMSO 50 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related HDAC Products |
|---|
| CM-444
CM-444 is an inhibitor for HDAC and DNA methyltransferases (DNMT) with IC50 values of 6 nM-0.6 μM and 1.8-2.3 μM, respectively. CM-444 is an inducer for the differentiation of acute myeloid leukemia cells. CM-444 exhibits anti-leukemic activity and improves the survival rate in mouse models. |
| CM-1758
CM-1758 is a histone deacetylase (HDAC) inhibitor. CM-1758 inhibits tumor growth in vivo. CM-1758 induces acetylation of non-histone proteins in acute myeloid leukemia cells. |
| T-518
T-518 is an orally active, selective, and blood-brain barrier permeable HDAC6 inhibitor with an IC50 value of 36 nM for human HDAC6. |
| SE-7552
SE-7552, a 2-(difluoromethyl)-1,3,4-oxadiazole (DFMO) derivative, is an orally active, highly selective, non-hydroxamate HDAC6 inhibitor with an IC50 of 33 nM. |
| BRD9757
BRD9757 is a potent, capless and selective HDAC6 inhibitor with an IC50 of 30 nM. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
